WO2000008202A3 - Modulateurs 3-methylidenyl-2-indolinone de proteine kinase - Google Patents

Modulateurs 3-methylidenyl-2-indolinone de proteine kinase Download PDF

Info

Publication number
WO2000008202A3
WO2000008202A3 PCT/US1999/017845 US9917845W WO0008202A3 WO 2000008202 A3 WO2000008202 A3 WO 2000008202A3 US 9917845 W US9917845 W US 9917845W WO 0008202 A3 WO0008202 A3 WO 0008202A3
Authority
WO
WIPO (PCT)
Prior art keywords
methylidenyl
protein kinase
indolinone
modulators
prodrugs
Prior art date
Application number
PCT/US1999/017845
Other languages
English (en)
Other versions
WO2000008202A2 (fr
WO2000008202A9 (fr
Inventor
Peng Cho Tang
Li Sun
Todd Anthony Miller
Congxin Liang
Ngoc My Tran
Anh Thi Nguyen
Asaad Nematalla
Original Assignee
Sugen Inc
Peng Cho Tang
Li Sun
Todd Anthony Miller
Congxin Liang
Ngoc My Tran
Anh Thi Nguyen
Asaad Nematalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc, Peng Cho Tang, Li Sun, Todd Anthony Miller, Congxin Liang, Ngoc My Tran, Anh Thi Nguyen, Asaad Nematalla filed Critical Sugen Inc
Priority to CA002383623A priority Critical patent/CA2383623A1/fr
Priority to US09/762,198 priority patent/US6531502B1/en
Priority to JP2000563824A priority patent/JP2002522452A/ja
Priority to AU54684/99A priority patent/AU5468499A/en
Publication of WO2000008202A2 publication Critical patent/WO2000008202A2/fr
Publication of WO2000008202A3 publication Critical patent/WO2000008202A3/fr
Publication of WO2000008202A9 publication Critical patent/WO2000008202A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne de nouveaux composés 3-méthylidényl-2-indolinone ainsi que leurs sels physiologiquement acceptables et leurs promédicaments. Ces composés modulent l'activité des protéines kinases et par conséquent sont supposés convenir à la prévention et au traitement des troubles cellulaires liés à la protéine kinase, comme par exemple le cancer.
PCT/US1999/017845 1998-01-21 1999-08-04 Modulateurs 3-methylidenyl-2-indolinone de proteine kinase WO2000008202A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002383623A CA2383623A1 (fr) 1998-08-04 1999-08-04 Modulateurs 3-methylidenyl-2-indolinone de proteine kinase
US09/762,198 US6531502B1 (en) 1998-01-21 1999-08-04 3-Methylidenyl-2-indolinone modulators of protein kinase
JP2000563824A JP2002522452A (ja) 1998-08-04 1999-08-04 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
AU54684/99A AU5468499A (en) 1998-08-04 1999-08-04 3-methylidenyl-2-indolinone modulators of protein kinase

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12925698A 1998-08-04 1998-08-04
US09/129,256 1998-08-04
US9547098P 1998-08-05 1998-08-05
US60/095,470 1998-08-05
US10217898P 1998-09-28 1998-09-28
US60/102,178 1998-09-28
US11610799P 1999-01-15 1999-01-15
US60/116,107 1999-01-15

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09762198 A-371-Of-International 1999-08-04
US09/762,198 A-371-Of-International US6531502B1 (en) 1998-01-21 1999-08-04 3-Methylidenyl-2-indolinone modulators of protein kinase
US10/383,690 Division US6855730B2 (en) 1998-08-05 2003-03-10 3-methylidenyl-2-indolinone modulators of protein kinase

Publications (3)

Publication Number Publication Date
WO2000008202A2 WO2000008202A2 (fr) 2000-02-17
WO2000008202A3 true WO2000008202A3 (fr) 2000-05-18
WO2000008202A9 WO2000008202A9 (fr) 2000-07-27

Family

ID=27492796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017845 WO2000008202A2 (fr) 1998-01-21 1999-08-04 Modulateurs 3-methylidenyl-2-indolinone de proteine kinase

Country Status (4)

Country Link
JP (1) JP2002522452A (fr)
AU (1) AU5468499A (fr)
CA (1) CA2383623A1 (fr)
WO (1) WO2000008202A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777417B2 (en) 2001-09-10 2004-08-17 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
KR20010101266A (ko) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 Ｊｎｋ 단백질 키나제의 억제제로서의 4-아릴옥신돌
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
CN1158283C (zh) 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
TR200101860T2 (tr) * 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
JP5336686B2 (ja) * 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
CA2407799A1 (fr) 2000-05-02 2001-11-08 Sugen, Inc. Derives d'acide acetique (2-oxindole-3-ylidenyl) et leur utilisation comme inhibiteurs de la proteine kinase
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2001094312A2 (fr) * 2000-06-02 2001-12-13 Sugen, Inc. Derives d'indolinone comme inhibiteurs de phosphatase/proteine kinase
EP1349852A2 (fr) * 2000-12-20 2003-10-08 Sugen, Inc. Indolinones 4-aryl substituees
US7186745B2 (en) 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002081466A1 (fr) * 2001-04-09 2002-10-17 Sugen, Inc. Promedicaments a base de derives 3-(pyrrol-2-ylmethylidene)-2-indolinone
EP1396490A1 (fr) * 2001-05-24 2004-03-10 Yamanouchi Pharmaceutical Co. Ltd. Derives de 3-quinoleine-2-(1h)-ylideneindoline-2-one
PE20030062A1 (es) 2001-05-30 2003-02-08 Sugen Inc Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
WO2003027111A1 (fr) * 2001-09-27 2003-04-03 Smithkline Beecham Corporation Composes chimiques
AU2003284572A1 (en) * 2002-11-22 2004-06-18 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US7517697B2 (en) * 2003-02-05 2009-04-14 Applied Biosystems, Llc Compositions and methods for preserving RNA in biological samples
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US7960548B2 (en) * 2005-04-29 2011-06-14 The Ohio State University Research Foundation Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis
WO2009030270A1 (fr) * 2007-09-03 2009-03-12 Novartis Ag Dérivés dhydroindoles utilisés pour traiter la maladie de parkinson
US8765748B2 (en) 2007-12-21 2014-07-01 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
CA2756568C (fr) 2009-04-06 2018-02-13 University Health Network Inhibiteurs de kinases et procede de traitement du cancer avec ceux-ci
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2012011516A (es) 2010-04-06 2013-03-08 Univ Health Network Inhibidores de cinasa, y metodo para tratar el cancer con los mismos.
WO2012048411A1 (fr) * 2010-10-13 2012-04-19 University Health Network Inhibiteurs de plk4 et méthode de traitement du cancer à l'aide de ceux-ci
WO2012142029A2 (fr) * 2011-04-10 2012-10-18 Florida A&M University Modulateurs sélectifs des récepteurs des œstrogènes pour traitement de troubles à médiation par les récepteurs des œstrogènes
AU2013314417B2 (en) 2012-09-13 2016-01-21 F. Hoffmann-La Roche Ag 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders
WO2014066840A1 (fr) 2012-10-26 2014-05-01 Regents Of The University Of Minnesota Inhibiteurs d'aurora kinase
EP3057593B1 (fr) 2013-10-18 2021-12-08 University Health Network Traitement du cancer du pancréas
EP3363799A4 (fr) * 2015-11-12 2018-12-05 LG Chem, Ltd. Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one
US10487054B2 (en) 2017-04-21 2019-11-26 Regents Of The University Of Minnesota Therapeutic compounds
PE20211054A1 (es) * 2018-10-05 2021-06-07 Ichnos Sciences S A Compuestos de indolinona para uso como inhibidores de map4k1
GR1010103B (el) * 2020-07-02 2021-10-18 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, 3-ινδολ-2-υλομεθυλιδενο-ινδολιν-2-ονες με δραση αναστολης της αυτοταξινης
WO2022006412A2 (fr) * 2020-07-02 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Conjugués d'inhibiteurs d'ampk et d'agents de dégradation de protac et utilisations associées

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5339992A (en) * 1991-07-10 1994-08-23 Societe De Prospection Et D'inventions Techniques (S.P.I.T. Tubular cartridge for storing and applying a non-solid product, and a drive and thrust assembly for the cartridge
US5374652A (en) * 1990-02-28 1994-12-20 Farmitalia Carlo Erba S R L 2-oxindole compounds which are useful as tyrosine kinase inhibitors
US5382593A (en) * 1992-07-21 1995-01-17 Adir Et Compagnie New 3-(hydroxybenzylidenyl)-indolin-2-ones
US5409949A (en) * 1991-07-12 1995-04-25 Farmitalia Carlo Erba S.R.L. Methylen-oxindole derivatives compositions and tyrosine kinase inhibition therewith
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374652A (en) * 1990-02-28 1994-12-20 Farmitalia Carlo Erba S R L 2-oxindole compounds which are useful as tyrosine kinase inhibitors
US5339992A (en) * 1991-07-10 1994-08-23 Societe De Prospection Et D'inventions Techniques (S.P.I.T. Tubular cartridge for storing and applying a non-solid product, and a drive and thrust assembly for the cartridge
US5409949A (en) * 1991-07-12 1995-04-25 Farmitalia Carlo Erba S.R.L. Methylen-oxindole derivatives compositions and tyrosine kinase inhibition therewith
US5382593A (en) * 1992-07-21 1995-01-17 Adir Et Compagnie New 3-(hydroxybenzylidenyl)-indolin-2-ones
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777417B2 (en) 2001-09-10 2004-08-17 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors

Also Published As

Publication number Publication date
WO2000008202A2 (fr) 2000-02-17
WO2000008202A9 (fr) 2000-07-27
JP2002522452A (ja) 2002-07-23
CA2383623A1 (fr) 2000-02-17
AU5468499A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
WO2000008202A3 (fr) Modulateurs 3-methylidenyl-2-indolinone de proteine kinase
EP0984930A4 (fr) Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
MXPA02008021A (es) Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
HK1126770A1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitor
WO2001090103A3 (fr) Promedicaments de derives de 3-(pyrrol-2-yl-methylidene)-2-indolinone
MXPA01006742A (es) Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
MY126235A (en) 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors.
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
WO2001029025A3 (fr) Inhibiteurs de tyrosine kinases
WO2001028993A3 (fr) Inhibiteurs tyrosine kinase
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
EP1247803A3 (fr) Composés d'indolinone et leur utilisation comme modulateurs de la protéine kinase
AU2212299A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
EP1218376A4 (fr) Inhibiteurs de tyrosine kinase
HU9803018D0 (en) Methods and compositions for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
WO2003032916A3 (fr) Organosulfures inhibiteurs de tyrosine phosphatases
WO2001042243A3 (fr) Inhibiteurs de proteine kinase
WO2001083450A3 (fr) Derives d'acide acetique (2-oxindole-3-ylidenyl) et leur utilisation comme inhibiteurs de la proteine kinase
WO2002028874A3 (fr) Inhibiteurs de prolifération tumorale
JO2199B1 (en) Replaced pyrrols
WO2002030942A3 (fr) Derives anhydro-glycidiques d'indolocarbazoles
AU2224800A (en) Compositions and methods for the treatment of tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-318, DESCRIPTION, REPLACED BY NEW PAGES 1-334; PAGES 319-345, CLAIMS, REPLACED BY NEW PAGES335-362; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 09762198

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 2383623

Country of ref document: CA